Skip to main content
Log in

Kinetics of allopurinol after single intravenous and oral doses

Noninteraction with benzbromarone and hydrochlorothiazide

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

An high-pressure liquid chromatographic method was used to measure allopurinol and oxipurinol in plasma and urine in 6 healthy volunteers after a single intravenous or oral dose of allopurinol. The influence of coadministrated benzbromarone and hydrochlorothiazide on the pharmacokinetics of allopurinol and oxipurinol was also investigated. After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32±1.08 min \((\bar x \pm SD)\) and an elimination half-life of 47.8±10.6 min. The total clearance of allopurinol was 11.37±2.70 ml/min/kg, whereas its renal clearance was only 1.73±0.79 ml/min/kg. Oxipurinol disappeared monoexponentially from plasma ith a mean half-life of 12.2±2.6 h. Its renal clearance was 0.42±0.091 ml/min/kg. After oral administration of allopurinol 300 mg the peak plasma concentration of 2.1±0.6 µg/ml (1.5×10−5 M) was reached within 30 to 120 min. The peak level of oxipurinol of 5.8±1.5 µg/ml (3.8×10−5 M) was found within 2 to 5 h after intravenous and oral allopurinol. The bioavailability of oral allopurinol computed from plasma data was 90.4±8.7%. The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration. It was concluded that about 10% of the oral dose was not absorbed and that 12% was eliminated by an unknown mechanism, presumably as riboside. The pharmacokinetics of allopurinol and oxipurinol were not significantly influenced by coadministration of benzbromarone or hydrochlorothiazide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Breithaupt H, Göbel G (1981) Determination of allopurinol and oxipurinol in biological fluids by high-performance liquid chromatography. J Chromatogr 226: 237–242

    PubMed  CAS  Google Scholar 

  • Brown M, Bye A (1977) The determination of allopurinol and oxipurinol in human plasma and urine. J Chromatogr 143: 195–202

    PubMed  CAS  Google Scholar 

  • Caskey CT, Ashton DM, Wyngaarden JB (1964) The enzymology of feedback inhibition of glutamine phosphoribosylpyrophosphate amidotransferase by purine ribonucleotides. J Biol Chem 239: 2570–2579

    PubMed  CAS  Google Scholar 

  • Elion GB, Callahan S, Nathan H, Bieber S, Rundles RW, Hitchings GH (1963) Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem Pharmacol 12: 85–93

    Article  CAS  Google Scholar 

  • Elion GB, Kovensky A, Hitchings GH, Metz E, Rundles RW (1966a) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 15: 863–880

    Article  PubMed  CAS  Google Scholar 

  • Elion EB, Taylor TJ, Hitchings GH (1966b) Kinetics of the inhibition of xanthine oxidase by allopurinol and alloxanthine. Fed Proc 25: 748

    Google Scholar 

  • Elion GB, Yü T-F, Gutman AB, Hitchings GH (1968) Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 45: 69–77

    Article  PubMed  CAS  Google Scholar 

  • Endele R, Lettenbauer G (1975) Hochdruckflüssigchromatographische Bestimmung von Allopurinol und Oxipurinol in Serum. J Chromatogr 115: 228–231

    Article  PubMed  CAS  Google Scholar 

  • Hall AP, Holloway VP, Scott JT (1964) HPP in the treatment of gout. Ann Rheum Dis 23: 439–446

    Article  PubMed  CAS  Google Scholar 

  • Hande K, Reed E, Chabner B (1978) Allopurinol Kinetics. Clin Pharmacol Ther 23: 598–605

    PubMed  CAS  Google Scholar 

  • Haughey DB, Lanse S, Imhoff Th, Tobin M, Schentag JJ (1979) Allopurinol sensitivity: report of two cases. Am J Pharm 36: 1377–1380

    CAS  Google Scholar 

  • Hitchings GH (1966) Effects of allopurinol in relation to purine biosynthesis. Ann Rheum Dis 25: 601–607

    PubMed  CAS  Google Scholar 

  • Janzen D, Mertz DP, Scheiffele E, Kühnhold O (1977) Renale Ausscheidung von Allantoin bei normourikämischen und hyperurikämischen Personen unter der Wirkung von Benzbromaron. Klin Wochenschr 55: 1071–1073

    Article  PubMed  CAS  Google Scholar 

  • Kelley WN, Rosenbloom FM, Miller J, Seegmiller JE (1968) An enzymatic basis for variation in response to allopurinol: hypoxanthine-guanine phosphoribosyltransferase deficiency. N Engl J Med 278: 287–293

    Article  PubMed  CAS  Google Scholar 

  • Klinenberg JR, Goldfinger SE, Seegmiller JE (1965) The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 62: 639–647

    PubMed  CAS  Google Scholar 

  • Kramer WG, Feldman S (1979) High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma. J Chromatogr 162: 94–97

    PubMed  CAS  Google Scholar 

  • Krenitsky TA, Elion GB, Strelitz RA, Hitchings GH (1967) Ribonucleosides of allopurinol and oxoallopurinol. J Biol Chem 242: 2675–2682

    PubMed  CAS  Google Scholar 

  • Lemieux G, Vinay R, Gougoux A, Michaud G (1973) Nature of the uricosuric action of benziodarone. Am J Physiol 224: 1440–1449

    PubMed  CAS  Google Scholar 

  • Lupton GP, Odom RB (1979) The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1: 365–374

    Article  PubMed  CAS  Google Scholar 

  • McKendrick MW, Geddes AM (1979) Allopurinol hypersensitivity. Br Med J 1: 988

    Article  PubMed  CAS  Google Scholar 

  • Rodnan GP, Robin JA, Tolchin SF, Elion GB (1975) Allopurinol and gouty hyperuricemia. J Am Med Assoc 231: 1143–1147

    Article  CAS  Google Scholar 

  • Rundles RW, Wyngaarden JB, Hitchings GH, Elion GB, Silberman HR (1963) Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout. Trans Assoc Am Physicians 76: 126–140

    CAS  Google Scholar 

  • Simmonds HA (1969) Urinary excretion of purines, pyrimidines, pyrazolopyrimidines in patients treated with allopurinol or oxipurinol. Clin Chim Acta 23: 353–364

    Article  PubMed  CAS  Google Scholar 

  • Sinclair DS, Fox IH (1975) The pharmacology of hypouricemic effect of benzbromarone. J Rheumatol 2: 437–445

    PubMed  CAS  Google Scholar 

  • Sorensen LB, Levinson DJ (1976) Clinical evaluation of benzbromarone. A new uricosuric drug. Arthritis Rheum 19: 183–190

    PubMed  CAS  Google Scholar 

  • Spector T, Johns DG (1970) Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo (3,4-d) pyrimidines. J Biol Chem 245: 5079–5085

    PubMed  CAS  Google Scholar 

  • Walter-Sack J, Gröbner W, Zöllner N (1979) Verlauf der Oxipurinol-Spiegel im Plasma nach akuter und chronischer Gabe von Allopurinol in verschiedenen galenischen Zubereitungen. Drug Res 29: 839–842

    CAS  Google Scholar 

  • Wood MH, Sebel E, O'Sullivan WJ (1972) Allopurinol and thiazides. Lancet 1: 751

    Article  PubMed  CAS  Google Scholar 

  • Young JL, Boswell RB, Nies AS (1974) Severe allopurinol hypersensitivity. Arch Intern Med 134: 553–558

    Article  PubMed  Google Scholar 

  • Yü T-F, Gutman AB (1964) Effect of allopurinol (4-hydroxypyrazolo (3,4-d) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 37: 885–898

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breithaupt, H., Tittel, M. Kinetics of allopurinol after single intravenous and oral doses. Eur J Clin Pharmacol 22, 77–84 (1982). https://doi.org/10.1007/BF00606429

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00606429

Key words

Navigation